Oxaliplatin - NanoCarrier
Alternative Names: DACH-platin micelle - NanoCarrier; DACH-platin polymeric micelle; Debio-0507; NC4016; ND-01Latest Information Update: 13 Jan 2022
Price :
$50 *
At a glance
- Originator NanoCarrier
- Developer NanoCarrier; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 31 Jan 2019 Phase I development is ongoing in USA (NanoCarrier pipeline, January 2019)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)